Systolic blood pressure reduction with tirzepatide in patients with type 2 diabetes: insights from SURPASS clinical program
Authors' conclusion
Tirzepatide-induced SBP reduction was primarily mediated through weight loss, with different degrees of contributions from weight-loss independent effects across the different trials. SBP reduction was not dependent on antihypertensive medication use but dependent on baseline SBP value, alleviating theoretical concerns of hypotension.
Study context
- Population
- Patients with T2D in the 5 SURPASS studies; safety population (all randomized patients who took ≥1 dose of study drug)5 SURPASS trials
- Comparison
- Tirzepatide 5, 10 and 15 mg vs comparators
- Primary endpoint
- Weight-loss dependent and weight-loss independent effects of tirzepatide on SBP reductions
- Follow-up
- 40 weeks
Methodological detailspooled and individual-study analyses
- Pooled and individual-study analyses
Primary result
As reported in the abstract
Difference in mean systolic blood pressure (SBP) change
- 1.3 to - 5.1 mmHg
Tirzepatide 5 mg
Difference in mean SBP change
- 1.7 to - 6.5 mmHg
Tirzepatide 10 mg
Difference in mean SBP change
- 3.1 to - 11.5 mmHg
Tirzepatide 15 mg
Further findings
Share of SBP difference vs insulin glargine explained by weight-loss independent effects, SURPASS-4 (established CVD)
- Weight-loss independent effects explained
- 33% to 57%
Correlation between change in body weight and SBP, pooled SURPASS-1 to −5
- Significant but weak correlation (r)
- 0.18 to 0.22
- P
- P < 0.001
SBP reduction by concomitant antihypertensive medication at baseline
- Similar reductions whether or not receiving antihypertensives; interaction p
- 0.77
SBP reduction by baseline SBP category
- Largest SBP reductions in highest baseline category (> 140 mmHg); no further decrease in first quartile (< 122 mmHg)
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →